43
Participants
Start Date
April 30, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
June 30, 2010
(FOLPI) Picoplatin with 5-FU and Leucovorin
Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
FOLPI
Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
FOLFOX
Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
Blokhin Russian Oncology Research Center - Phase 1, Moscow
Semashko Central Clinical Hospital #2 - Phase 1, Moscow
Yaroslavl Regional Oncology Center - Phase 1, Yaroslavl
Republic Oncology Center of the Ministry of Healthcare of Karelia Republic - Phase 2, Petrozavodsk
Leningrad Regional Oncology Center, Chemotherapy Department - Phase 2, Kuzmolovsky Village
St. Petersburg Academy of Postgraduate Education - Phase 2, Saint Petersburg
St. Petersburg Mechnikov State Medical Academy - Phase 2, Saint Petersburg
St. Petersburg City Oncology Center - Phase 1, Saint Petersburg
Medical Radiology Research Center of Russian Academy of Medical Sciences- Phase 1, Obninsk
Rostov Research Institute of Oncology- Phase 2, Rostov-na-Dony
Voronezh Regional Clinical Oncology Center - Phase 2, Voronezh
Regional Oncology Center, Chemotherapy Department - Phase 2, Engel's
Regional Oncology Center - Phase 2, Astrakhan
Kazan Oncology Center, Kazan'
Regional Clinical Oncology Center - Phase 2, Ulyanovsk
Chelyabinsk Regional Oncology Center - Phase 1, Chelyabinsk
Lead Sponsor
Poniard Pharmaceuticals
INDUSTRY